MYC与HSF1协同作用，驱动高级别浆液性卵巢癌对Polo样激酶1抑制剂沃拉替尼的敏感性。
MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer.
作者信息
Williams Imade, O'Malley Matthew, DeHart Haddie, Walker Bobby, Ulhaskumar Vrushabh, Jothirajah Pranav, Ray Haimanti, Landrum Lisa M, Delaney Joe R, Nephew Kenneth P, Carpenter Richard L
机构信息
Medical Sciences Program, Indiana University School of Medicine, Bloomington, Indiana.
Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.
出版信息
Cancer Res Commun. 2025 Feb 1;5(2):253-266. doi: 10.1158/2767-9764.CRC-24-0400.
We show that HSF1 and MYC genes are co-amplified in more than 30% of HGSOC and demonstrate that HSF1 and MYC functionally cooperate to drive the growth of HGSOC cells. This work provides the foundation for HSF1 and MYC co-amplification as a biomarker for treatment efficacy of the polo-like kinase 1 inhibitor volasertib in HGSOC.
我们发现，在超过30%的高级别浆液性卵巢癌（HGSOC）中，HSF1和MYC基因存在共扩增现象，并证明HSF1和MYC在功能上协同作用以驱动HGSOC细胞的生长。这项工作为HSF1和MYC共扩增作为polo样激酶1抑制剂沃拉替尼治疗HGSOC疗效的生物标志物奠定了基础。
Zotero 插件